Helix BioPharmaHBPCF 28 14-Day RSI is 0.15 as of Jul. 03, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,423 Biotechnology companies, Helix BioPharma ranks better than 85.24% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-03), Helix BioPharma's 14-Day RSI is 0.15.
The industry rank for Helix BioPharma's 14-Day RSI or its related term are showing as below:
HBPCF's 14-Day RSI is ranked better than 85.24% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs HBPCF: 0.15
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Helix BioPharma 14-Day RSI Related Terms
HBPCF vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Helix BioPharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a 14-Day RSI of 0.15 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #210 out of 1423 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Helix BioPharma's 14-Day RSI too high?
Helix BioPharma's current 14-Day RSI is 0.15. The Biotechnology industry median 14-Day RSI is 49.99. Helix BioPharma's value of 0.15 is 99.7% below this industry median. Based on the distribution chart, Helix BioPharma ranks #210 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #210 out of 1423 companies for 14-Day RSI. This places Helix BioPharma in the top 15% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 49.99. Helix BioPharma's value of 0.15 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Helix BioPharma's current 14-Day RSI of 0.15 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current 14-Day RSI is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 14-Day RSI of 0.15. The current 14-Day RSI is 0.15 and 99.7% below the Biotechnology industry median of 49.99. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 14-Day RSI is 0.15 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 